Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
The risk of colorectal cancer (CRC) is significantly higher in patients with chronic kidney disease (CKD), regardless of a history of transplant, according to the results of a systematic review and meta-analysis.
There is a strong association between smoking duration and colorectal polyps, independent of smoking intensity, cessation and other potential confounders, reports a recent study. Such association is more robust with distal rather than proximal polyps, and with serrated polyps rather than adenomas.
The addition of pertuzumab to trastuzumab and chemotherapy did not significantly affect overall survival (OS) of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric or gastroesophageal junction cancer, according to the JACOB* trial.
History of legal termination of pregnancy (TOP) is the strongest predictor of perinatal maternal mortality among patients with acute fatty liver of pregnancy (AFLP), followed by total bilirubin and serum creatinine, according to a recent study.
Caspase-2, a protein-cleaving enzyme, is a key component in the onset and progression of non-alcoholic steatohepatitis (NASH), a new study shows.
In patients receiving foecal microbiota transplantation (FMT) for the treatment of Clostridium difficile infection (CDI), high levels of Candida albicans may be associated with poor outcomes, a recent study has shown.
The nucleotide analogue tenofovir disoproxil fumarate (TDF) is associated with mild renal impairment in a minority of patients being treated for chronic hepatitis B virus (HBV) infection, a study by the Chinese University of Hong Kong (CUHK) has shown.
Special Reports
There is an increasing number of studies that shed light on the importance of our gut microbiota. Probiotics are live microorganisms that confer health benefits on the host when administered in adequate amounts. With new data emerging about their proposed benefits in maintaining intestinal health, probiotics continue to gain popularity amongst consumers.
Advancements in genomics has paved the way for better classifications of colorectal cancers (CRC) and the use of precision therapy.
In this issue of MIMS Gastroenterology Supplement, we bring you clinical updates related to hepatitis B, and also a symposium highlight in conjunction with the launch of tenofovir disoproxil fumarate (Ricovir®; Mylan Laboratories) in Malaysia.
Last August, the article 'Role of General Practitioners in Early Detection of Inflammatory Bowel Disease' highlighted proper screening and early specialist referral by the general practitioner (GP) as vital components in reducing the burden of inflammatory bowel disease (IBD). This year, the focus is on the role of GPs in co-managing a patient with IBD at the follow-up phase.
Nonalcoholic fatty liver disease (NAFLD), including simple steatosis and nonalcoholic steatohepatitis (NASH), is widely considered as the liver manifestation of the metabolic syndrome. It is a major cause of liver disease worldwide and its prevalence is expected to rise in tandem with the rising prevalence of obesity and diabetes mellitus. Recently, MIMS Doctor spoke to Associate Professor Dr Wah Kheong Chan, a Consultant Physician and Gastroenterologist at the University of Malaya Medical Centre and University of Malaya Specialist Centre, to provide an update on NAFLD, with a particular emphasis on the use of silymarin for the treatment of NASH. Here are the highlights from the interview.
Constipation is a common disorder which adversely affects the wellbeing and quality of life of patients.1 Recently, MIMS Doctor spoke to Associate Prof Dr Raja Affendi Raja Ali on the landscape of constipation in Malaysia, emphasizing on effective and early management of the condition.
DUKORAL – Inactivated Vibrio cholerae O1 serogroup & recombinant cholera toxin B subunit (WC/rCTB) vaccine (oral) – AJ Biologics
Conference Reports
A weekly dose escalation of regorafenib was superior to starting with the standard dose of 160 mg/day for patients with refractory metastatic colorectal cancer (mCRC), according to the ReDOS* trial presented at the ASCO GI Cancers Symposium 2018.
Patients with inflammatory bowel disease (IBD) who had primary nonresponse ─ or inadequate response to the initial loading doses ─ to an anti-tumour necrosis factor (TNF) agent were less likely to respond to second-line biologics compared with those who had secondary loss of response (LOR) or intolerance to the primary therapy, according to a systematic review and meta-analysis presented at the Crohn's & Colitis Congress (CCC) 2018 held recently in Las Vegas, Nevada, US.
Studies demonstrate conflicting findings on impact of obesity on treatment response, outcomes in IBD
Obesity does not appear to have a significant influence on treatment response and clinical outcomes in patients with inflammatory bowel disease (IBD), according to two studies presented at the 2018 Crohn’s & Colitis Congress (CCC).
Use of the gut-selective anti-integrin monoclonal antibody vedolizumab was associated with favourable treatment outcomes in patients with inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn’s disease, according to studies presented at the 2018 Crohn’s & Colitis Congress (CCC).
Pembrolizumab demonstrated promising results in several outcomes among patients with advanced hepatocellular carcinoma (HCC) whose disease progressed on or who were unable to tolerate treatment with sorafenib, findings from the KEYNOTE-224* trial show.
Rifaximin, an antibiotic that has been approved for treating IBS-D*, may also benefit patients with Crohn's disease (CD), suggests a study presented at the Crohn's & Colitis Congress (CCC) 2018.
Using the JAK* inhibitor tofacitinib as induction therapy for Crohn’s disease (CD) can promote disease remission in certain patients selected based on baseline endoscopic evidence of inflammation, according to a post hoc analysis presented at the recent Crohn's & Colitis Congress (CCC) 2018, Las Vegas, Nevada, US.
.jpg)
